0001209191-21-025115.txt : 20210405 0001209191-21-025115.hdr.sgml : 20210405 20210405160911 ACCESSION NUMBER: 0001209191-21-025115 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210401 FILED AS OF DATE: 20210405 DATE AS OF CHANGE: 20210405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Watts Ryan J. CENTRAL INDEX KEY: 0001724310 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38311 FILM NUMBER: 21805417 MAIL ADDRESS: STREET 1: C/O DENALI THERAPEUTICS INC. STREET 2: 151 OYSTER POINT BLVD., 2ND FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Denali Therapeutics Inc. CENTRAL INDEX KEY: 0001714899 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463872213 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 866-8548 MAIL ADDRESS: STREET 1: 161 OYSTER POINT BLVD. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-01 0 0001714899 Denali Therapeutics Inc. DNLI 0001724310 Watts Ryan J. C/O DENALI THERAPEUTICS INC. 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2021-03-09 5 G 0 E 40000 0.00 D 2265742 I See footnote Common Stock 2021-04-01 4 S 0 5232 55.521 D 2260510 I See footnote Common Stock 2021-04-01 4 S 0 8516 56.876 D 2251994 I See footnote Common Stock 2021-04-01 4 S 0 4586 57.314 D 2247408 I See footnote Common Stock 156691 D The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee. The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.245 to $56.235 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.32 to $57.03 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $57.038 to $58.02 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Includes 156,691 restricted stock units. /s/ Tyler Nielsen, by power of attorney 2021-04-05